<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01022580</url>
  </required_header>
  <id_info>
    <org_study_id>H10842-33541-01A</org_study_id>
    <secondary_id>U01HL094338</secondary_id>
    <nct_id>NCT01022580</nct_id>
  </id_info>
  <brief_title>Trial of Late Surfactant for Prevention of Bronchopulmonary Dysplasia</brief_title>
  <acronym>TOLSURF</acronym>
  <official_title>Trial of Late Surfactant for Prevention of Bronchopulmonary Dysplasia: A Study in Ventilated Preterm Infants Receiving Inhaled Nitric Oxide</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Roberta Ballard</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if late doses of Infasurf surfactant given when&#xD;
      patients are receiving inhaled nitric oxide will interact to improve surfactant function and&#xD;
      increase survival without BPD in treated infants.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multi-center, blinded, randomized controlled clinical trial to evaluate the effects&#xD;
      of booster doses of exogenous surfactant (InfasurfÂ®, calfactant) in addition to inhaled&#xD;
      nitric oxide (iNO) on the outcome of survival without bronchopulmonary dysplasia (BPD, or&#xD;
      chronic lung disease of prematurity, characterized by chronic lung dysfunction) at 36 weeks'&#xD;
      post-menstrual age (PMA) in extremely low gestational age (ELGAN) infants that are at high&#xD;
      risk of the development of BPD. This multi-center trial, with a planned enrollment of 524&#xD;
      infants, will also enable us to evaluate for any adverse effects of late surfactant treatment&#xD;
      on short- and long-term outcomes, as we will be collecting data on effects of dosing of late&#xD;
      surfactant, co-morbidities of prematurity and neurodevelopmental and pulmonary outcome at 1&#xD;
      year and 24 months corrected age. In addition, we will collect biological specimens for&#xD;
      evaluation of the effects of late surfactant replacement therapy (administered as described&#xD;
      in this trial) on surfactant function and inflammatory markers.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">January 2016</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Survival Without BPD at 36 Weeks Post Menstrual Age.</measure>
    <time_frame>36 weeks post menstrual age +/- 1 week</time_frame>
    <description>BPD was diagnosed as need for respiratory support with either positive pressure and/or oxygen as evaluated by physiological oxygen/flow reduction.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Survival Without BPD at 40 Weeks</measure>
    <time_frame>40 weeks PMA +/- 1 week</time_frame>
    <description>BPD was diagnosed as need for respiratory support with either positive pressure and/or oxygen as evaluated by physiological oxygen/flow reduction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiratory Outcomes of TOLSURF Infants at 1 Year Corrected Age</measure>
    <time_frame>1 year</time_frame>
    <description>Evaluation of respiratory outcome through the first 12 months after birth. questionnaires were administered by phone at 3,6,9 and 12 months to determine respiratory resource use (medications, home support, and hospitalization) No Pulmonary Morbidity (NoPM) was reported for infants who had no resource use in any quarter and Persistent PM was reported for infants having resource use in 3 or 4 quarters.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary Outcomes Through 2 Years of Age</measure>
    <time_frame>2 years</time_frame>
    <description>Evaluation of pulmonary outcome at 24 months of age. Evaluation of persistent wheezing based on reported wheezing during both first and second year of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Neurodevelopmental Impairment (NDI) at 2 Years.</measure>
    <time_frame>2 years</time_frame>
    <description>At 24 months corrected age, children underwent neuropsychological testing with the Bayley Scales of Infant Development-Third Edition (Bayley-3), and composite cognitive, language, and motor scores were collected as well as subscale scores in receptive and expressive speech and fine and gross motor. Infants with greater than one impairment as identified by testing were classified as having neurodevelopmental impairment.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">511</enrollment>
  <condition>Bronchopulmonary Dysplasia</condition>
  <arm_group>
    <arm_group_label>Infasurf surfactant (ONY, Inc.)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Infants already receiving inhaled nitric oxide will receive scheduled doses of late surfactant (Infasurf) on study days 0, 2, 4, 6 and 8.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham (No Treatment)</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Infants already receiving inhaled nitric oxide will receive &quot;Sham (no treatment)&quot; doses on study days 0,2,4,6, and 8.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Infasurf surfactant (ONY, Inc.)</intervention_name>
    <description>Late doses of Infasurf 3ml/kg will be given to infants on study days 0, 2, 4, 6 and 8 as long as infant remains intubated.</description>
    <arm_group_label>Infasurf surfactant (ONY, Inc.)</arm_group_label>
    <other_name>Treatment</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sham (No Treatment)</intervention_name>
    <description>Late doses of Sham (No treatment) will be given to infants on study days 0, 2, 4, 6 and 8 as long as infant remains intubated.</description>
    <arm_group_label>Sham (No Treatment)</arm_group_label>
    <other_name>Control</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  &lt;=28 0/7 weeks gestational age&#xD;
&#xD;
          -  Day of life 7-14&#xD;
&#xD;
          -  Intubated and mechanically ventilated&#xD;
&#xD;
          -  Plan to treat with inhaled nitric oxide&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Serious congenital malformations or chromosomal abnormalities&#xD;
&#xD;
          -  Life expectancy &lt;7 days from enrollment&#xD;
&#xD;
          -  Clinically unstable&#xD;
&#xD;
          -  Less tha 48 hours since last dose surfactant&#xD;
&#xD;
          -  Ability to obtain 36 week primary outcome information is unlikely&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>14 Days</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roberta A Ballard, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Arkansas - Arkansas Childrens Hospital</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alta Bates Medical Center</name>
      <address>
        <city>Berkeley</city>
        <state>California</state>
        <zip>94705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oakland Children's Hospital</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wolfson Children's Hospital and Shands HospitaL</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Hospital for Children</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>All Children's Hospital</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern Memorial Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Memorial Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Childrens Hospital and Clinics of Minnesota- Minneapolis</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Minnesota Medical School</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital and Clinics of Minnesota - St Paul</name>
      <address>
        <city>Saint Paul</city>
        <state>Minnesota</state>
        <zip>55102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Mercy Hospital</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Women's and Children's Hospital of Buffalo</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14222</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stony Brook University Medical Center</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11794</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Forest University- Forsyth Hospital and Brenner Hospital</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina(MUSC)</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UT Memphis- Memphis Medical Center</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38103-2807</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UT Houston Health Science Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-1503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Children's Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington, Seattle</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195-6320</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Ballard RA, Truog WE, Cnaan A, Martin RJ, Ballard PL, Merrill JD, Walsh MC, Durand DJ, Mayock DE, Eichenwald EC, Null DR, Hudak ML, Puri AR, Golombek SG, Courtney SE, Stewart DL, Welty SE, Phibbs RH, Hibbs AM, Luan X, Wadlinger SR, Asselin JM, Coburn CE; NO CLD Study Group. Inhaled nitric oxide in preterm infants undergoing mechanical ventilation. N Engl J Med. 2006 Jul 27;355(4):343-53. Erratum in: N Engl J Med. 2007 Oct 4;357(14):1444-5.</citation>
    <PMID>16870913</PMID>
  </reference>
  <reference>
    <citation>Ballard PL, Merrill JD, Truog WE, Godinez RI, Godinez MH, McDevitt TM, Ning Y, Golombek SG, Parton LA, Luan X, Cnaan A, Ballard RA. Surfactant function and composition in premature infants treated with inhaled nitric oxide. Pediatrics. 2007 Aug;120(2):346-53.</citation>
    <PMID>17671061</PMID>
  </reference>
  <reference>
    <citation>Truog WE, Ballard PL, Norberg M, Golombek S, Savani RC, Merrill JD, Parton LA, Cnaan A, Luan X, Ballard RA; Nitric Oxide (to Prevent) Chronic Lung Disease Study Investigators. Inflammatory markers and mediators in tracheal fluid of premature infants treated with inhaled nitric oxide. Pediatrics. 2007 Apr;119(4):670-8.</citation>
    <PMID>17403837</PMID>
  </reference>
  <results_reference>
    <citation>Ballard RA, Keller RL, Black DM, Ballard PL, Merrill JD, Eichenwald EC, Truog WE, Mammel MC, Steinhorn RH, Rogers EE, Ryan RM, Durand DJ, Asselin JM, Bendel CM, Bendel-Stenzel EM, Courtney SE, Dhanireddy R, Hudak ML, Koch FR, Mayock DE, McKay VJ, O'Shea TM, Porta NF, Wadhawan R, Palermo L; TOLSURF Study Group. Randomized Trial of Late Surfactant Treatment in Ventilated Preterm Infants Receiving Inhaled Nitric Oxide. J Pediatr. 2016 Jan;168:23-29.e4. doi: 10.1016/j.jpeds.2015.09.031. Epub 2015 Oct 21.</citation>
    <PMID>26500107</PMID>
  </results_reference>
  <results_reference>
    <citation>Wai KC, Hibbs AM, Steurer MA, Black DM, Asselin JM, Eichenwald EC, Ballard PL, Ballard RA, Keller RL; Trial of Late Surfactant (TOLSURF) Study Group. Maternal Black Race and Persistent Wheezing Illness in Former Extremely Low Gestational Age Newborns: Secondary Analysis of a Randomized Trial. J Pediatr. 2018 Jul;198:201-208.e3. doi: 10.1016/j.jpeds.2018.02.032. Epub 2018 Apr 4.</citation>
    <PMID>29627188</PMID>
  </results_reference>
  <results_reference>
    <citation>Keller RL, Eichenwald EC, Hibbs AM, Rogers EE, Wai KC, Black DM, Ballard PL, Asselin JM, Truog WE, Merrill JD, Mammel MC, Steinhorn RH, Ryan RM, Durand DJ, Bendel CM, Bendel-Stenzel EM, Courtney SE, Dhanireddy R, Hudak ML, Koch FR, Mayock DE, McKay VJ, Helderman J, Porta NF, Wadhawan R, Palermo L, Ballard RA; TOLSURF Study Group. The Randomized, Controlled Trial of Late Surfactant: Effects on Respiratory Outcomes at 1-Year Corrected Age. J Pediatr. 2017 Apr;183:19-25.e2. doi: 10.1016/j.jpeds.2016.12.059. Epub 2017 Jan 16.</citation>
    <PMID>28100402</PMID>
  </results_reference>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>November 19, 2009</study_first_submitted>
  <study_first_submitted_qc>November 30, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 1, 2009</study_first_posted>
  <results_first_submitted>August 26, 2015</results_first_submitted>
  <results_first_submitted_qc>April 21, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">May 13, 2021</results_first_posted>
  <last_update_submitted>April 21, 2021</last_update_submitted>
  <last_update_submitted_qc>April 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Francisco</investigator_affiliation>
    <investigator_full_name>Roberta Ballard</investigator_full_name>
    <investigator_title>Professor of Pediatrics</investigator_title>
  </responsible_party>
  <keyword>nitric oxide</keyword>
  <keyword>surfactant</keyword>
  <keyword>BPD</keyword>
  <keyword>prematurity</keyword>
  <keyword>neonates</keyword>
  <keyword>iNO</keyword>
  <keyword>pulmonary outcome</keyword>
  <keyword>neurodevelopmental outcome</keyword>
  <keyword>Infasurf</keyword>
  <keyword>lung function</keyword>
  <keyword>Surfactant Dysfunction</keyword>
  <keyword>Bronchopulmonary Dysplasia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bronchopulmonary Dysplasia</mesh_term>
    <mesh_term>Hyperplasia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Surfactants</mesh_term>
    <mesh_term>Calfactant</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Infasurf Surfactant (ONY, Inc.)</title>
          <description>Infants already receiving inhaled nitric oxide will receive scheduled doses of late surfactant (Infasurf) on study days 0, 2, 4, 6 and 8.&#xD;
Infasurf surfactant (ONY, Inc.): Late doses of Infasurf 3ml/kg will be given to infants on study days 0, 2, 4, 6 and 8.</description>
        </group>
        <group group_id="P2">
          <title>Sham</title>
          <description>Infants already receiving inhaled nitric oxide will not receive additional doses of late surfactant (Infasurf).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="252"/>
                <participants group_id="P2" count="259"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="234">Survived to discharge</participants>
                <participants group_id="P2" count="237">Survived to discharge.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Infasurf Surfactant (ONY, Inc.)</title>
          <description>Infants already receiving inhaled nitric oxide will receive scheduled doses of late surfactant (Infasurf) on study days 0, 2, 4, 6 and 8.&#xD;
Infasurf surfactant (ONY, Inc.): Late doses of Infasurf 3ml/kg will be given to infants on study days 0, 2, 4, 6 and 8.</description>
        </group>
        <group group_id="B2">
          <title>Sham</title>
          <description>Infants already receiving inhaled nitric oxide will not receive additional doses of late surfactant (Infasurf).</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="252"/>
            <count group_id="B2" value="259"/>
            <count group_id="B3" value="511"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>weeks</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Gestational Age Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25.2" spread="1.2"/>
                    <measurement group_id="B2" value="25.2" spread="1.2"/>
                    <measurement group_id="B3" value="25.2" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="109"/>
                    <measurement group_id="B2" value="121"/>
                    <measurement group_id="B3" value="230"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="143"/>
                    <measurement group_id="B2" value="138"/>
                    <measurement group_id="B3" value="281"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="56"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="227"/>
                    <measurement group_id="B2" value="225"/>
                    <measurement group_id="B3" value="452"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="99"/>
                    <measurement group_id="B2" value="91"/>
                    <measurement group_id="B3" value="190"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="134"/>
                    <measurement group_id="B2" value="157"/>
                    <measurement group_id="B3" value="291"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Respiratory Severity Score (RSS) - MAP x FiO2</title>
          <description>Respiratory Severity Score (RSS) equals the mean airway pressure (on ventilator or Nasal CPAP) X fraction of inspired oxygen (FiO2). Range can be 0 - 16, higher scores indicating greater disease severity.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.7" spread="2.3"/>
                    <measurement group_id="B2" value="3.8" spread="2.2"/>
                    <measurement group_id="B3" value="3.75" spread="3.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Birthweight</title>
          <units>grams</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="700.1" spread="173.2"/>
                    <measurement group_id="B2" value="702.3" spread="156.0"/>
                    <measurement group_id="B3" value="701" spread="160"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Survival Without BPD at 36 Weeks Post Menstrual Age.</title>
        <description>BPD was diagnosed as need for respiratory support with either positive pressure and/or oxygen as evaluated by physiological oxygen/flow reduction.</description>
        <time_frame>36 weeks post menstrual age +/- 1 week</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Infasurf Surfactant (ONY, Inc.)</title>
            <description>Infants already receiving inhaled nitric oxide will receive scheduled doses of late surfactant (Infasurf) on study days 0, and repeated Q24-72 hours as long as infant remains ventilated.&#xD;
Infasurf surfactant (ONY, Inc.): Late doses of Infasurf 3ml/kg will be given to infants on study days 0, and repeated Q24-72 hours as long as infant remains ventilated.</description>
          </group>
          <group group_id="O2">
            <title>Sham</title>
            <description>Infants already receiving inhaled nitric oxide will receive scheduled sham (nothing done) doses of late surfactant (nothing done).&#xD;
Sham (nothing done) doses will be given to infants on study days 0,and repeated Q24-72 hours as long as infant remains ventilated.</description>
          </group>
        </group_list>
        <measure>
          <title>Survival Without BPD at 36 Weeks Post Menstrual Age.</title>
          <description>BPD was diagnosed as need for respiratory support with either positive pressure and/or oxygen as evaluated by physiological oxygen/flow reduction.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="252"/>
                <count group_id="O2" value="259"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79"/>
                    <measurement group_id="O2" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.89</p_value>
            <method>unadj GEE</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Survival Without BPD at 40 Weeks</title>
        <description>BPD was diagnosed as need for respiratory support with either positive pressure and/or oxygen as evaluated by physiological oxygen/flow reduction.</description>
        <time_frame>40 weeks PMA +/- 1 week</time_frame>
        <population>Infants who were No BPD at 36 wk were imputed to be No BPD at 40 wk. Infants discharged on oxygen without a challenge test were assigned Yes BPD.</population>
        <group_list>
          <group group_id="O1">
            <title>Infasurf Surfactant (ONY, Inc.)</title>
            <description>Infants already receiving inhaled nitric oxide will receive scheduled doses of late surfactant (Infasurf) upon entry into study.&#xD;
Repeat Infasurf surfactant (ONY, Inc.) doses will be given to infants still ventilated on study days (+/- 24 hours): 2, 4, 6 and 8.</description>
          </group>
          <group group_id="O2">
            <title>Sham</title>
            <description>Infants already receiving inhaled nitric oxide will receive Sham (no treatment) upon entry into study.&#xD;
Repeat Sham doses will be given to infants still ventilated on study days (+/- 24 hours): 2, 4, 6 and 8.</description>
          </group>
        </group_list>
        <measure>
          <title>Survival Without BPD at 40 Weeks</title>
          <description>BPD was diagnosed as need for respiratory support with either positive pressure and/or oxygen as evaluated by physiological oxygen/flow reduction.</description>
          <population>Infants who were No BPD at 36 wk were imputed to be No BPD at 40 wk. Infants discharged on oxygen without a challenge test were assigned Yes BPD.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="252"/>
                <count group_id="O2" value="259"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="148"/>
                    <measurement group_id="O2" value="140"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.33</p_value>
            <method>unadj GEE</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Respiratory Outcomes of TOLSURF Infants at 1 Year Corrected Age</title>
        <description>Evaluation of respiratory outcome through the first 12 months after birth. questionnaires were administered by phone at 3,6,9 and 12 months to determine respiratory resource use (medications, home support, and hospitalization) No Pulmonary Morbidity (NoPM) was reported for infants who had no resource use in any quarter and Persistent PM was reported for infants having resource use in 3 or 4 quarters.</description>
        <time_frame>1 year</time_frame>
        <population>Infants who survived to discharge and had data from questionaires available</population>
        <group_list>
          <group group_id="O1">
            <title>Infasurf Surfactant (ONY, Inc.)</title>
            <description>Infants who received inhaled nitric oxide and late doses of surfactant will have respiratory questionaires administered by phone at 3,6,9 and 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Sham</title>
            <description>Infants who received only inhaled nitric oxide will have respiratory questionaires administered by phone at 3,6,9 and 12 months</description>
          </group>
        </group_list>
        <measure>
          <title>Respiratory Outcomes of TOLSURF Infants at 1 Year Corrected Age</title>
          <description>Evaluation of respiratory outcome through the first 12 months after birth. questionnaires were administered by phone at 3,6,9 and 12 months to determine respiratory resource use (medications, home support, and hospitalization) No Pulmonary Morbidity (NoPM) was reported for infants who had no resource use in any quarter and Persistent PM was reported for infants having resource use in 3 or 4 quarters.</description>
          <population>Infants who survived to discharge and had data from questionaires available</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="208"/>
                <count group_id="O2" value="240"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Home respiratory support</title>
                  <measurement_list>
                    <measurement group_id="O1" value="80"/>
                    <measurement group_id="O2" value="118"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No PM</title>
                  <measurement_list>
                    <measurement group_id="O1" value="54"/>
                    <measurement group_id="O2" value="47"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Persistent PM</title>
                  <measurement_list>
                    <measurement group_id="O1" value="74"/>
                    <measurement group_id="O2" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pulmonary Outcomes Through 2 Years of Age</title>
        <description>Evaluation of pulmonary outcome at 24 months of age. Evaluation of persistent wheezing based on reported wheezing during both first and second year of life.</description>
        <time_frame>2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Infasurf Surfactant (ONY, Inc.)</title>
            <description>Infants already receiving inhaled nitric oxide will receive scheduled doses of late surfactant (Infasurf) on study days 0, 2, 4, 6 and 8.&#xD;
Infasurf surfactant (ONY, Inc.): Late doses of Infasurf 3ml/kg will be given to infants on study days 0, 2, 4, 6 and 8.</description>
          </group>
          <group group_id="O2">
            <title>Sham</title>
            <description>Infants already receiving inhaled nitric oxide will not receive additional doses of late surfactant (Infasurf).</description>
          </group>
        </group_list>
        <measure>
          <title>Pulmonary Outcomes Through 2 Years of Age</title>
          <description>Evaluation of pulmonary outcome at 24 months of age. Evaluation of persistent wheezing based on reported wheezing during both first and second year of life.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="203"/>
                <count group_id="O2" value="217"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91"/>
                    <measurement group_id="O2" value="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Neurodevelopmental Impairment (NDI) at 2 Years.</title>
        <description>At 24 months corrected age, children underwent neuropsychological testing with the Bayley Scales of Infant Development-Third Edition (Bayley-3), and composite cognitive, language, and motor scores were collected as well as subscale scores in receptive and expressive speech and fine and gross motor. Infants with greater than one impairment as identified by testing were classified as having neurodevelopmental impairment.</description>
        <time_frame>2 years</time_frame>
        <population>Neurodevelopmental testing occurred with only 322 participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Infasurf Surfactant (ONY, Inc.)</title>
            <description>Infants already receiving inhaled nitric oxide will receive scheduled doses of late surfactant (Infasurf) on study days 0, 2, 4, 6 and 8.&#xD;
Infasurf surfactant (ONY, Inc.): Late doses of Infasurf 3ml/kg will be given to infants on study days 0, 2, 4, 6 and 8.</description>
          </group>
          <group group_id="O2">
            <title>Sham</title>
            <description>Infants already receiving inhaled nitric oxide will not receive additional doses of late surfactant (Infasurf).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Neurodevelopmental Impairment (NDI) at 2 Years.</title>
          <description>At 24 months corrected age, children underwent neuropsychological testing with the Bayley Scales of Infant Development-Third Edition (Bayley-3), and composite cognitive, language, and motor scores were collected as well as subscale scores in receptive and expressive speech and fine and gross motor. Infants with greater than one impairment as identified by testing were classified as having neurodevelopmental impairment.</description>
          <population>Neurodevelopmental testing occurred with only 322 participants.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="154"/>
                <count group_id="O2" value="168"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Infasurf Surfactant (ONY, Inc.)</title>
          <description>Infants already receiving inhaled nitric oxide will receive scheduled doses of late surfactant (Infasurf) on study days 0, 2, 4, 6 and 8.&#xD;
Infasurf surfactant (ONY, Inc.): Late doses of Infasurf 3ml/kg will be given to infants on study days 0, 2, 4, 6 and 8 as long as infant remains intubated.</description>
        </group>
        <group group_id="E2">
          <title>Sham (No Treatment)</title>
          <description>Infants already receiving inhaled nitric oxide will receive &quot;Sham (no treatment)&quot; doses on study days 0,2,4,6, and 8.&#xD;
Sham (No Treatment): Late doses of Sham (No treatment) will be given to infants on study days 0, 2, 4, 6 and 8 as long as infant remains intubated.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="252"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="259"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="252"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="259"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="29" subjects_affected="29" subjects_at_risk="252"/>
                <counts group_id="E2" events="24" subjects_affected="24" subjects_at_risk="259"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="141" subjects_at_risk="252"/>
                <counts group_id="E2" subjects_affected="153" subjects_at_risk="259"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>PDA Requiring Treatment</sub_title>
                <description>Incidence of infants who's PDA worsened to the point of needing treatment.</description>
                <counts group_id="E1" events="89" subjects_affected="89" subjects_at_risk="252"/>
                <counts group_id="E2" events="95" subjects_affected="95" subjects_at_risk="259"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>ROP Class 4-5 or surgery</sub_title>
                <counts group_id="E1" events="34" subjects_affected="34" subjects_at_risk="252"/>
                <counts group_id="E2" events="29" subjects_affected="29" subjects_at_risk="259"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>NEC</sub_title>
                <description>Incidence of new or worsened NEC after enrollment.</description>
                <counts group_id="E1" events="27" subjects_affected="27" subjects_at_risk="252"/>
                <counts group_id="E2" events="24" subjects_affected="24" subjects_at_risk="259"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>IVH New or Worsened</sub_title>
                <description>Evaluation of new or worsened IVH after enrollment.</description>
                <counts group_id="E1" events="33" subjects_affected="33" subjects_at_risk="252"/>
                <counts group_id="E2" events="35" subjects_affected="35" subjects_at_risk="259"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Sepsis</sub_title>
                <description>Incidence new episodes of culture proven sepsis after enrollment.</description>
                <counts group_id="E1" events="141" subjects_affected="141" subjects_at_risk="252"/>
                <counts group_id="E2" events="153" subjects_affected="153" subjects_at_risk="259"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Possible limitations of the trial: Infants 1) may not have had enough surfactant dysfunction to benefit from replacement; or 2) had irreversible lung damage prior to enrollment; or 3) The dose/frequency of replacement surfactant was inadequate.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Roberta A Ballard, MD</name_or_title>
      <organization>University of California, San Francisco</organization>
      <phone>415-476-4193</phone>
      <email>roberta.ballard@ucsf.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

